A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Status:
NOT_YET_RECRUITING
Trial end date:
2033-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
Vepugratinib and placebo will be administered in combination with existing standard of care (SOC) therapy.
Study participation could last up to approximately 6 years.